These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 1331538

  • 1. Epstein-Barr virus nuclear protein 2 is a critical determinant for tumor growth in SCID mice and for transformation in vitro.
    Cohen JI, Picchio GR, Mosier DE.
    J Virol; 1992 Dec; 66(12):7555-9. PubMed ID: 1331538
    [Abstract] [Full Text] [Related]

  • 2. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation.
    Cohen JI, Wang F, Kieff E.
    J Virol; 1991 May; 65(5):2545-54. PubMed ID: 1850028
    [Abstract] [Full Text] [Related]

  • 3. Residues 231 to 280 of the Epstein-Barr virus nuclear protein 2 are not essential for primary B-lymphocyte growth transformation.
    Harada S, Yalamanchili R, Kieff E.
    J Virol; 1998 Dec; 72(12):9948-54. PubMed ID: 9811732
    [Abstract] [Full Text] [Related]

  • 4. An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro.
    Robertson ES, Tomkinson B, Kieff E.
    J Virol; 1994 Mar; 68(3):1449-58. PubMed ID: 8107208
    [Abstract] [Full Text] [Related]

  • 5. The EBNA-2 arginine-glycine domain is critical but not essential for B-lymphocyte growth transformation; the rest of region 3 lacks essential interactive domains.
    Tong X, Yalamanchili R, Harada S, Kieff E.
    J Virol; 1994 Oct; 68(10):6188-97. PubMed ID: 8083959
    [Abstract] [Full Text] [Related]

  • 6. Epstein-Barr virus recombinants from overlapping cosmid fragments.
    Tomkinson B, Robertson E, Yalamanchili R, Longnecker R, Kieff E.
    J Virol; 1993 Dec; 67(12):7298-306. PubMed ID: 8230453
    [Abstract] [Full Text] [Related]

  • 7. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.
    Cohen JI, Wang F, Mannick J, Kieff E.
    Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9558-62. PubMed ID: 2556717
    [Abstract] [Full Text] [Related]

  • 8. Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs.
    Robertson E, Kieff E.
    J Virol; 1995 Feb; 69(2):983-93. PubMed ID: 7815566
    [Abstract] [Full Text] [Related]

  • 9. Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa.
    Robertson ES, Grossman S, Johannsen E, Miller C, Lin J, Tomkinson B, Kieff E.
    J Virol; 1995 May; 69(5):3108-16. PubMed ID: 7707539
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA.
    Dillner J, Kallin B, Ehlin-Henriksson B, Timar L, Klein G.
    Int J Cancer; 1985 Mar 15; 35(3):359-66. PubMed ID: 2982749
    [Abstract] [Full Text] [Related]

  • 13. EBNA-2 of herpesvirus papio diverges significantly from the type A and type B EBNA-2 proteins of Epstein-Barr virus but retains an efficient transactivation domain with a conserved hydrophobic motif.
    Ling PD, Ryon JJ, Hayward SD.
    J Virol; 1993 Jun 15; 67(6):2990-3003. PubMed ID: 8388484
    [Abstract] [Full Text] [Related]

  • 14. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1.
    Wrightham MN, Stewart JP, Janjua NJ, Pepper SD, Sample C, Rooney CM, Arrand JR.
    Virology; 1995 Apr 20; 208(2):521-30. PubMed ID: 7538250
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.
    Wang F, Tsang SF, Kurilla MG, Cohen JI, Kieff E.
    J Virol; 1990 Jul 20; 64(7):3407-16. PubMed ID: 2352328
    [Abstract] [Full Text] [Related]

  • 16. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
    Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E.
    J Virol; 1990 May 20; 64(5):2309-18. PubMed ID: 2157887
    [Abstract] [Full Text] [Related]

  • 17. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein.
    Abbot SD, Rowe M, Cadwallader K, Ricksten A, Gordon J, Wang F, Rymo L, Rickinson AB.
    J Virol; 1990 May 20; 64(5):2126-34. PubMed ID: 2157875
    [Abstract] [Full Text] [Related]

  • 18. Host cell-dependent regulation of growth transformation-associated Epstein-Barr virus antigens in somatic cell hybrids.
    Contreras-Salazar B, Klein G, Masucci MG.
    J Virol; 1989 Jun 20; 63(6):2768-72. PubMed ID: 2542588
    [Abstract] [Full Text] [Related]

  • 19. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.
    Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS.
    J Exp Med; 1993 Feb 01; 177(2):339-49. PubMed ID: 8381153
    [Abstract] [Full Text] [Related]

  • 20. Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV.
    Yalamanchili R, Tong X, Grossman S, Johannsen E, Mosialos G, Kieff E.
    Virology; 1994 Nov 01; 204(2):634-41. PubMed ID: 7941331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.